help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dunstan, C. R.
Right arrow Articles by Seibel, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dunstan, C. R.
Right arrow Articles by Seibel, M. J.
Endocrinology Vol. 145, No. 7 3084-3086
Copyright © 2004 by The Endocrine Society

Fibroblast Growth Factor 23: A Phosphatonin Regulating Phosphate Homeostasis?

Colin R. Dunstan, Hong Zhou and Markus J. Seibel

Bone Biology Laboratory (C.R.D., H.Z., M.J.S.), ANZAC Research Institute, Sydney, New South Wales 2139, Australia; and Endocrinology Department (M.J.S.), Faculty of Medicine, University of Sydney, Sydney, New South Wales 2006, Australia

Address all correspondence and requests for reprints to: Dr. Colin R. Dunstan, Bone Biology Laboratory, ANZAC Research Institute, Hospital Road, Concord, New South Wales 2139, Australia. E-mail cdunstan{at}anzac.edu.au.

Inorganic phosphate (Pi) is a critical circulating ion required to support multiple essential cellular processes dependent on phosphorus, including energy transport, nucleotide synthesis, and intracellular cell signaling. In addition, Pi is essential with calcium for the mineralization of bone matrix through the formation of hydroxyapatite crystals [Ca10(PO4)6(OH)2]. Normally, levels of Pi in the plasma are maintained in the range of approximately 2.5–4.5 mg/dl (0.26–0.47 mmol/liter). Regulation of Pi levels in plasma is important, as demonstrated by the harmful effects of low levels (phosphopenic osteomalacia/rickets, muscle weakness) or high levels (secondary hyperparathyroidism, renal and other soft tissue calcification) (1).

In this issue, Larsson et al. (2) describe phosphaturia due to decreased renal reabsorption of Pi, hypophosphatemia, and osteomalacia/rickets in mice with targeted transgenic overexpression of fibroblast growth factor 23 (FGF23) in osteoblasts. This phenotype illustrates a role for FGF23 in Pi metabolism and a potential role for FGF23 in Pi homeostasis. These studies illustrate the ability of FGF23 to mimic some, but not all, of the effects of PTH on Pi homeostasis, illustrating a potential physiological role for FGF23 in Pi metabolism.

It has been apparent for a number of years that circulating factors apart from PTH or the related molecule PTHrP are able to produce hyperphosphaturia and hypophosphatemia. However, the nature of these molecules and their potential physiological role in phosphate metabolism and homeostasis has only recently begun to be determined. The name "phosphatonin" has been suggested for this class of molecules, which includes FGF23 (3, 4).

Significant homeostatic regulation of Pi occurs through PTH actions on renal Pi handling and through PTH and Pi regulation of 25-hydroxyvitamin D 1{alpha} hydroxylase activity. 25-Hydroxyvitamin D 1{alpha} hydroxylase acts to increase levels of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] with resultant increases in gut phosphate absorption (Fig. 1Go). However, the presence of additional Pi regulators (phosphatonins) have been demonstrated through the study of three rare conditions, x-linked hypophosphatemic rickets (XLH) (5, 6), autosomal dominant hypophosphatemic rickets (ADHR) (7), and tumor-induced osteomalacia (8, 9, 10, 11). The mouse analog of XLH, the hyp mouse (12), has demonstrated most convincingly, through parabiosis and renal transplant experiments, that one or several circulating factor/s in hyp mice could transfer the phosphaturia and hypophosphatemia to a paired wild-type littermate (13) but transplant of a hyp kidney could not (14). The genetic defect in both humans and the hyp mouse was found to be an inactivating mutation in an endopeptidase called PHEX, suggesting that the function of PHEX may be to inactivate a phosphatonin and that, in the absence of active PHEX, an excess of soluble phosphatonin accumulates in the circulation (5, 6, 9). The recessive nature of this mutation in females would support the concept of an inactivating mutation. Another possibility would be that PHEX normally activates or stabilizes an inhibitor or degradative pathway for phosphatonins.



View larger version (19K):
[in this window]
[in a new window]
  		FIG. 1. Regulation of plasma Pi levels by PTH and 1,25(OH)2D3. Elevated plasma Pi levels induce PTH secretion through the reciprocal relationship between Pi and calcium levels. PTH decreases urinary Pi reabsorption, thus increasing excretion of Pi. Elevated Pi levels suppress 1,25(OH)2D3 production, causing a reduction in gut Pi absorption. The concerted effects lower plasma Pi levels. Low Pi exerts the opposite effects, resulting decreased Pi excretion and increased Pi gut absorption.

 
ADHR is biochemically similar to XLH in that there is phosphaturia, hypophosphatemia, and low or inappropriately normal 1,25(OH)2D3. The genetic basis of ADHR has been found to be a mutation in the FGF family member FGF23 (7). The main effect of the mutation would seem to be a stabilization of this molecule through increased resistance to proteolytic breakdown (15, 16, 17), although there are also reports of increased activity (15). FGF23 has been found to have many of the attributes of a phosphatonin. Recombinant FGF23, or Chinese hamster ovary cell-secreted FGF23 induces phosphaturia and hypophosphatemia (16) (Fig. 2Go).



View larger version (20K):
[in this window]
[in a new window]
  		FIG. 2. Regulation of plasma Pi by FGF23 and other phosphatonins. FGF23 acts like PTH to decrease phosphate reabsorption and thus produce hyperphosphaturia. Unlike PTH, which acts to increase 1,25(OH)2D3 synthesis, FGF23 acts to inhibit 1,25(OH)2D3 synthesis (30 ) and to block the normal 1,25(OH)2D3 response to hypophosphatemia. Phosphaturia coupled with reduced Pi absorption from the gut leads to hypophosphatemia, which results in the defective mineralization of bone matrix that characterizes rickets.

 
In tumor-induced osteomalacia, tumor-secreted factor/s induce urinary phosphate wasting and associated hypophosphatemia and osteomalacia, which resolve if the tumor is successfully resected. Studies of differential gene expression have identified concurrent overexpression of normal FGF23 (18, 19) and also two other factors with phosphaturic action, matrix extracellular phosphoglycoprotein (8, 20) and FRIZZLED-related protein-4 (9). The concurrent expression of multiple phosphatonin molecules is suggestive of some linkage in regulation of expression of these genes and that phenotype is dependent on interactions between these and perhaps other factors.

The recent report of the effects of gene deletion of FGF23 (21) is also interesting because these mice have an opposite phenotype with hyperphosphatemia and markedly elevated 1,25(OH)2D3 levels. These effects of gene deletion add additional strong evidence that FGF23 has an integral role in Pi metabolism. Intriguingly, these mice also have an osteomalacic phenotype. Whether this reflects a direct role of FGF23 in bone mineralization or an indirect effect through the hyperphosphatemia, high vitamin D levels, or another mechanism remains to be determined.

It would be intellectually tempting to link PHEX and the phosphatonins to a common pathway; however, current data are not sufficient to do this definitively (1). Full-length FGF23 has not been definitively identified as a substrate for PHEX (22), although smaller fragments are cut by this enzyme (23) and matrix extracellular phosphoglyocoprotein may be stabilized by PHEX (24). Whereas FGF23 levels are frequently elevated in tumor-induced osteomalacia, XLH, and ADHR (10), there is considerable overlap with normal populations or populations with other disorders (25, 26, 27, 28).

It remains unclear whether FGF23, or the other phosphatonin candidates, have a role in physiological phosphate homeostasis or whether their role is in the regulation of local or tissue-specific aspects of phosphate handling. To unravel this question, it will be important to determine the relevant tissue or cell sources of these molecules, to determine how they are regulated, and to identify local vs. systemic effects. A very recent publication addresses the systemic actions of FGF23 by use of tissue nonspecific transgenic overexpression under a chicken ß-actin promotor (29). Larsson et al., in this issue, refine this approach to begin to address the tissue-specific effects for FGF23 through bone-specific overexpression of FGF23 in osteoblasts under the {alpha}1(I) collagen promoter. In both of these models, mice have high circulating levels of FGF23 and the phenotype of hypophosphatemic rickets/osteomalacia. In these mice, hypophosphatemia results from hyperphosphaturia associated with reduced renal expression of the type IIa sodium-phosphate cotransporter, and inappropriately low levels 1,25(OH)2D3 levels.

The high circulating level of FGF23 in the transgenic mice produced by the models of Larsson et al. (2) does not allow clear differentiation of local from systemic effects, although FGF23 levels would be expected to be highest in the bone microenvironment. However, organ cultures and primary cell cultures from the bone-specific transgenic mouse will provide useful in vitro tools to address local effects and interactions at the tissue levels with other phosphatonin candidates. The generation of mice with tissue-specific but lower or regulated expression will also enable this issue to be further examined.


   Footnotes
 
Abbreviations: ADHR, Autosomal dominant hypophosphatemic rickets; 1,25(OH)2D3, 1,25-dihydroxyvitamin D3; FGF23, fibroblast growth factor 23; Pi, inorganic phosphate; XLH, x-linked hypophosphatemic rickets.

Received March 18, 2004.

Accepted for publication April 1, 2004.


   References
Top
 References
 

  1. Schiavi SC, Kumar R 2004 The phosphatonin pathway: new insights in phosphate homeostasis. Kidney Int 65:1–14[CrossRef][Medline]
  2. Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren Ö, Tenenhouse HS, Jüppner H, Jonsson KB 2004 Transgenic mice expressing fibroblast growth factor 23 under the control of the {alpha}1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 145:3087–3094[Abstract/Free Full Text]
  3. Kumar R 1997 Phosphatonin — a new phosphaturetic hormone? (lessons from tumour-induced osteomalacia and X-linked hypophosphataemia). Nephrol Dial Transplant 12:11–13[Free Full Text]
  4. Schiavi SC, Moe OW 2002 Phosphatonins: a new class of phosphate-regulating proteins. Curr Opin Nephrol Hypertens 11:423–430[CrossRef][Medline]
  5. 1995 A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet 11:130–136
  6. Holm IA, Huang X, Kunkel LM 1997 Mutational analysis of the PEX gene in patients with X-linked hypophosphatemic rickets. Am J Hum Genet 60:790–797[Medline]
  7. 2000 Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. The ADHR Consortium. Nat Genet 26:345–348
  8. Rowe PS, de Zoysa PA, Dong R, Wang HR, White KE, Econs MJ, Oudet CL 2000 MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 67:54–68[CrossRef][Medline]
  9. Berndt T, Craig TA, Bowe AE, Vassiliadis J, Reczek D, Finnegan R, Jan De Beur SM, Schiavi SC, Kumar R 2003 Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J Clin Invest 112:785–794[CrossRef][Medline]
  10. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S2002 Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87:4957–4960
  11. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2001 Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98:6500–6505[Abstract/Free Full Text]
  12. Beck L, Soumounou Y, Martel J, Krishnamurthy G, Gauthier C, Goodyer CG, Tenenhouse HS 1997 Pex/PEX tissue distribution and evidence for a deletion in the 3' region of the Pex gene in X-linked hypophosphatemic mice. J Clin Invest 99:1200–1209[Medline]
  13. Meyer Jr RA, Meyer MH, Gray RW 1989 Parabiosis suggests a humoral factor is involved in X-linked hypophosphatemic rickets in mice. J Bone Miner Res 4:493–500[Medline]
  14. Nesbitt T, Coffman TM, Griffiths F, Drezner MK 1995 Crosstransplantation of kidney in normal and Hyp mice. Evidence that the Hyp mouse phenotype is unrelated to an intrinsic renal defect. J Clin Invest 89:1454–1459
  15. Bai XY, Miao D, Goltzman D, Karaplis AC 2003 The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem 278:9843–9849[Abstract/Free Full Text]
  16. Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2002 Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 143:3179–3182[Abstract]
  17. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ 2001 Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60:2079–2086[CrossRef][Medline]
  18. White KE, Jonsson KB, Carn G, Hampson G, Spector TD, Mannstadt M, Lorenz-Depiereux B, Miyauchi A, Yang IM, Ljunggren O, Meitinger T, Strom TM, Juppner H, Econs MJ 2001 The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab 86:497–500[Abstract/Free Full Text]
  19. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H 2003 Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. New Engl J Med 348:1656–1663[Abstract/Free Full Text]
  20. Rowe PS, Kumagai Y, Gutierrez G, Garrett IR, Blacher R, Rosen D, Cundy J, Navvab S, Chen D, Drezner MK, Quarles LD, Mundy GR 2004 MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 34:303–319[Medline]
  21. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T 2004 Targeted ablation of FGF23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113:561–568.[CrossRef][Medline]
  22. Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, Quarles LD 2003 Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 278:37419–37426[Abstract/Free Full Text]
  23. Campos M, Couture C, Hirata IY, Juliano MA, Loisel TP, Crine P, Juliano L, Boileau G, Carmona AK 2003 Human recombinant endopeptidase PHEX has a strict S1' specificity for acidic residues and cleaves peptides derived from fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein. Biochem J 373:271–279[CrossRef][Medline]
  24. Guo R, Rowe PS, Liu S, Simpson LG, Xiao ZS, Darryl Quarles LD 2002 Inhibition of MEPE cleavage by Phex. Biochem Biophys Res Comm 297:38–45[CrossRef][Medline]
  25. Singh RJ, Kumar R 2003 Fibroblast growth factor 23 concentrations in humoral hypercalcemia of malignancy and hyperparathyroidism. Mayo Clin Proc 78:826–829[Medline]
  26. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB 2003 Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64:2272–2279[CrossRef][Medline]
  27. Weber TJ, Liu S, Indridason OS, Quarles LD 2003 Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 18:1227–1234[CrossRef][Medline]
  28. Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, Waguespack S, Gupta A, Hannon T, Econs MJ, Bianco P, Gehron Robey P 2003 FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112:683–692[CrossRef][Medline]
  29. Shimada T, Urakawa I, Yamazaki Y, Hasegawa H, Hino R, Yoneya T, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2004 FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Comm 314:409–414[CrossRef][Medline]
  30. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T 2004 FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:429–435[CrossRef][Medline]



This article has been cited by other articles:


Home page
 EndocrinologyHome page
A. E. Drummond, M. Tellbach, M. Dyson, and J. K. Findlay
Fibroblast Growth Factor-9, a Local Regulator of Ovarian Function
Endocrinology, August 1, 2007; 148(8): 3711 - 3721.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dunstan, C. R.
Right arrow Articles by Seibel, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dunstan, C. R.
Right arrow Articles by Seibel, M. J.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals